Jim Simons's position in Genmab is currently worth $75.8M. That's 0.10% of their equity portfolio (227th largest holding). The first Genmab trade was made in Q1 2020. Since then Jim Simons bought shares thirteen more times and sold shares on eight occasions. The investor's estimated purchase price is $81.7M, resulting in a loss of 7.3%.